Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2014, Article ID 949317, 3 pages
http://dx.doi.org/10.1155/2014/949317
Case Report

Occurrence of Psoriatic Arthritis during Interferon Beta 1a Treatment for Multiple Sclerosis

1Clinical Investigation Center Biotherapy INSERM CIC-1431, FHU INCREASE, University Hospital Besançon, Place Saint Jacques, 25000 Besançon, France
2Department of Rheumatology, University Hospital Besançon, 25000 Besançon, France
3Department of Therapeutics, University of Franche-Comté, 25000 Besançon, France
4Pathogens and Inflammation Laboratory, University of Franche-Comté, UPRES EA 4266, SFR FED 4234, 25000 Besançon, France
5Department of Neurology, University Hospital Besançon, 25000 Besançon, France
6Department of Rheumatology, Belfort-Montbéliard Hospital, 90000 Belfort, France
7Department of Neurology, Belfort-Montbéliard Hospital, 90000 Belfort, France

Received 16 February 2014; Accepted 31 March 2014; Published 15 April 2014

Academic Editor: Masataka Kuwana

Copyright © 2014 Éric Toussirot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Interferon beta (IFN-β) is the first line therapy of relapsing-remitting multiple sclerosis. IFN-β is a cytokine that can contribute to the development of systemic autoimmune disease including psoriasis. The development or the exacerbation of psoriasis during IFN-β treatment has been previously observed. We report the occurrence of arthritis and dactylitis in a multiple sclerosis patient with preexisting psoriasis diagnosed as a psoriatic arthritis. The IL-23/Th17 pathway is involved in psoriasis and psoriatic arthritis and it has been suggested that IFN-β therapy in patients with Th17-mediated disease may be detrimental. Together with previous similar reports, our case suggests that IFN-β should certainly be used with caution in patients with concomitant systemic autoimmune disease with IL-23/Th17 involvement.